| DNA Repair Pathway | Defective mutation in Breast Cancer | Therapeutic Intervention |
| Homologous recombination | BRCA1, BRCA2, ATM, ATR, CHK1, CHK2, BARD1, RAD51D, NBS1, PALB2, FANCD2, CtIP, PALB2 [17, 51–54] | Platinum based chemotherapies [55], PARP inhibitors (immune checkpoint blockade) |
| Non-homologous end-joining | DNA-PK, KU70/80 [56] | DNAPK inhibitors, ionizing radiation |
| Mismatch repair | MLH1, MSH2, MSH6, PMS2 [57, 58] | Immune checkpoint blockade |
| Base excision repair, Nucleotide excision repair, Translesional synthesis | APE1, XRCC1, ERCC2 [59, 60] | APE1 inhibitors [61] |
|
|